Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?

Abstract

Coronary disease accounts for the majority of deaths among patients with diabetes and the thrombotic milieu accelerated by diabetes results in unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI) or death. Upstream use of a glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor with percutaneous coronary intervention (PCI) as part of an early invasive approach is preferred. However substantial numbers of patients present to rural or non-teaching hospitals without immediate access to a catheterization laboratory. Enhanced GP IIb/IIIa receptor mobilization, TXA2 production and platelet activation together present an extensive thrombotic challenge that may not be overcome with current doses of GP IIb/IIIa inhibitors when used without PCI. Heterogeneity of platelet aggregometric analysis may have identified GP IIb/IIIa doses used in clinical trials that may not fully overcome the thrombotic challenge in patients with diabetes. GUSTO-IV ACS failed to demonstrate a difference in mortality when used without PCI. The PURSUIT trial provided evidence that eptifibatide decreases death or non-fatal myocardial infarction (MI) in the main group and in the diabetic subgroup. Reductions in this primary endpoint were driven by the reduction in non-fatal MI. The PRISM and PRISM-PLUS trials demonstrated a reduction in death, MI or refractory ischaemia at 48 h or 7 days in the main cohort but not specifically in patients with diabetes. Data supporting use of GP IIb/IIIa inhibitors are inconsistent, raising the question of whether these agents should be used at all without PCI. Variability in experimental methodology of platelet aggregometry and selection of anticoagulant used during dose finding studies may have generated doses that are insufficient to overcome the thrombotic burden. A new marker of active inflammation, sCD40L is found to be upregulated at subtherapeutic doses of GP IIb/IIIa inhibitors, suggesting that rebound inflammatory processes may partially account for absence of clear evidence of benefit with some GP IIb/IIIa inhibitors in patients with diabetes experiencing UA/NSTEMI.

• Authors: M A Silva, P J Gandhi
• Journal: Journal of clinical pharmacy and therapeutics (J Clin Pharm Ther) Vol. 29 Issue 6 Pg. 497-510 (Dec 2004) ISSN: 0269-4727 [Print] England
• PMID: 15584937 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Immunoglobulin Fab Fragments
• Peptides
• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex
• Tyrosine
• Tirofiban
• Eptifibatide
• Abciximab

Topics

• Abciximab
• Angina, Unstable (complications, drug therapy)
• Antibodies, Monoclonal (pharmacokinetics, therapeutic use)
• Clinical Trials as Topic
• Diabetes Complications
• Diabetes Mellitus (drug therapy)
• Eptifibatide
• Humans
• Immunoglobulin Fab Fragments (therapeutic use)
• Myocardial Infarction (complications, drug therapy)
• Peptides (pharmacokinetics, therapeutic use)
• Platelet Aggregation Inhibitors (pharmacokinetics, therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Tirofiban
• Tyrosine (analogs & derivatives, pharmacokinetics, therapeutic use)